1871 completed, 650 recruiting, 462 terminated, 435 unknown. 1553 Phase 2, 1445 Phase 1, 525 Not applicable, 238 Phase 3, 173 Early Phase 1.
Follow Neoplasms, Neuroepithelial: new trials by email Literature Review of Neoplasms, Neuroepithelial trials Research Report on Neoplasms, Neuroepithelial
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Using Brain Stimulation and Behavioral Therapy to Increase Extent of Resection in Low-Grade Gliomas RNS System Implantation - Glioma, Glioma Intracranial | Not applicable | Not yet recruiting | Medical College of Wisconsin | 3 | 2028-08-01 | 2026-10-13 |
| Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal Disease, or Recurrent High Grade Glioma JBI-778 - Brain Metastases From Solid Tumors, Leptomeningeal Disease | Phase 1 / Phase 2 | Not yet recruiting | Jubilant Therapeutics Inc. | 113 | 2028-04-01 | 2026-08-07 |
| Residual IDH1-Mutant Tumor Cell Quantification Study UR-ddPCR - Glioma | Not applicable | Not yet recruiting | NYU Langone Health | 105 | 2027-08-01 | 2026-09-29 |
| H3K27M-specific Immune Effector Cells Targeting DMG/DIPG H3K27M-EIEs - Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-30 | 2026-08-27 |
| Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography - Recurrent Ganglioneuroblastoma, Recurrent Neuroblastoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 76 | 2027-06-25 | 2026-10-22 |
| Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG) ADI-PEG 20 (Arginine deiminase pegylated), Temozolomide (TMZ), Standard of Care Radiation Therapy (RT) - Glioblastoma, High-Grade Glioma (WHO III-IV) | Phase 1 / Phase 2 | Not yet recruiting | Sabine Mueller, MD, PhD | 97 | 2027-06-01 | 2026-09-15 |
| DLL3 CAR-T Therapy Targeting Brain Tumors 4SCAR DLL3 T cells - Glioblastoma of Cerebellum | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-01 | 2026-09-01 |
| Metronomic Temozolomide With Dexbrompheniramine for Recurrent High-Grade Glioma/Glioblastoma Dexbrompheniramine, Temozolomide - High Grade Glioma, Glioblastoma | Phase 1 / Phase 2 | Not yet recruiting | University of Nebraska | 41 | 2027-06-01 | 2026-10-05 |
| MeFAMP for Imaging System A Amino Acid Transport in Primary and Metastatic Brain Tumors [F-18]MeFAMP PET - Healthy Volunteers, Recurrent Glioma | Early Phase 1 | Not yet recruiting | University of Alabama at Birmingham | 28 | 2027-04-01 | 2026-08-20 |
| Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma Cerebraca wafer, Temozolomide (for relapsed malignant glioma) - Recurrent Glioblastoma, IDH-Wildtype | Phase 2 / Phase 3 | Not yet recruiting | Everfront Biotech Co., Ltd. | 175 | 2027-04-01 | 2026-09-10 |
| Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPG Opdualag - High Grade Glioma, Diffuse Intrinsic Pontine Glioma | Phase 2 | Not yet recruiting | Nationwide Children's Hospital | 12 | 2027-03-01 | 2026-09-09 |
| Safety and Efficacy Study of Safusidenib in Participants With Grade 2 IDH1-Mutant Glioma Safusidenib, Placebo - Grade 2 Glioma (Astrocytoma or Oligodendroglioma) With an IDH1 Mutation, Astrocytoma IDH Mutant Grade 2 | Phase 3 | Not yet recruiting | Nuvation Bio Inc. | 140 | 2027-03-01 | 2026-07-17 |
| Safusidenib for Patients With Newly Diagnosed IDH1-mutant CNS WHO Grade 3 Oligodendroglioma and Astrocytoma - a Single Arm Phase II Study Safusidenib - Glioma : Oligodendroglioma or Astrocytoma | Phase 2 | Not yet recruiting | University of Zurich | 20 | 2027-03-01 | 2026-09-21 |
| Oral Gallium Maltolate for Recurrent Glioblastoma Gallium Maltolate, Surgical Intervention - Glioblastoma | Early Phase 1 | Not yet recruiting | Medical College of Wisconsin | 8 | 2027-03-01 | 2026-09-23 |
| Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease Safusidenib - Grade 2 IDH1-mutant Glioma, Grade 3 IDH1-mutant Glioma | Phase 2 | Recruiting | Nuvation Bio Inc. | 40 | 2027-03-01 | 2026-10-20 |
| FPS-ZM1 With or Without Dexamethasone for Controlling Post Operative Cerebral Edema in Patients With Glioblastoma Biospecimen Collection, Computed Tomography, Dexamethasone - Glioblastoma, Malignant Glioma | Phase 1 | Not yet recruiting | City of Hope Medical Center | 24 | 2027-02-17 | 2026-08-27 |
| Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG) Tovorafenib - High Grade Glioma (HGG) of the Brain With BRAF Aberration, High Grade Glioma (III or IV) | Phase 2 | Not yet recruiting | Nationwide Children's Hospital | 79 | 2027-02-01 | 2026-10-20 |
| IDH1-vac in Patients With Newly Diagnosed IDH1R132H-positive High-grade Astrocytomas IDH1-vac, IS-vac, Temozolomide (TMZ) - Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4 | Phase 2 | Not yet recruiting | German Cancer Research Center | 216 | 2027-02-01 | 2026-10-22 |
| Efficacy of Zoster Vaccination in Glioblastoma Patients Additional vaccination against shingles (herpes zoster), Standard of care treatment without additional vaccination - Glioblastoma (GBM) | Phase 4 | Not yet recruiting | University Hospital, Essen | 230 | 2027-01-02 | 2026-04-23 |
| NG101m Adjuvant Therapy in Glioblastoma Patients Intensity-modulated radiation therapy, Temozolomide, NG101m - Glioblastoma Multiforme | Phase 1 / Phase 2 | Not yet recruiting | NeuGATE Theranostics | 52 | 2027-01-01 | 2025-10-21 |
Showing 20 of 4135. Sign in to see all of them.
Glioblastoma (2068) · Glioma (1448) · Brain Neoplasms (895) · Astrocytoma (677) · Neuroblastoma (652) · Gliosarcoma (487) · Central Nervous System Neoplasms (445) · Oligodendroglioma (410) · Medulloblastoma (314) · Neoplasms (283) · Sarcoma (223) · Ependymoma (219) · Recurrence (201) · Osteosarcoma (153) · Breast Neoplasms (149)
Neoplasms, Glandular and Epithelial (4131) · Neoplasms, Nerve Tissue (4123) · Neoplasms by Histologic Type (4122) · Neuroectodermal Tumors (4116) · Neoplasms, Germ Cell and Embryonal (4091) · Neoplasms (3852) · Glioma (1879) · Neoplasms by Site (1727) · Astrocytoma (1617) · Nervous System Diseases (1426) · Nervous System Neoplasms (1309) · Central Nervous System Diseases (1101) · Brain Diseases (1086) · Neuroectodermal Tumors, Primitive (947)
Temozolomide (572) · Radiotherapy (329) · Bevacizumab (209) · Cyclophosphamide (174) · Carboplatin (150) · Magnetic Resonance Spectroscopy (150) · Etoposide (136) · Vincristine (123) · Radiation (114) · Irinotecan (105) · Filgrastim (99) · Cisplatin (81) · Lomustine (78) · Topotecan (77) · Melphalan (71)
National Cancer Institute (NCI) (284) · Children's Oncology Group (105) · Memorial Sloan Kettering Cancer Center (100) · M.D. Anderson Cancer Center (82) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (72) · Duke University (70) · St. Jude Children's Research Hospital (55) · Mayo Clinic (38) · Novartis Pharmaceuticals (38) · Dana-Farber Cancer Institute (35) · City of Hope Medical Center (33) · Jonsson Comprehensive Cancer Center (33) · European Organisation for Research and Treatment of Cancer - EORTC (32) · Washington University School of Medicine (31) · Case Comprehensive Cancer Center (30)
United States (2521) · China (337) · Canada (334) · France (329) · Germany (222) · United Kingdom (204) · Italy (186) · Netherlands (181) · Australia (178) · Spain (174) · Switzerland (159) · Belgium (104) · Austria (81) · Denmark (73) · South Korea (65)
Annick Desjardins, MD, FRCPC (16) · Nader Sanai, MD (16) · Stanislaw R. Burzynski, MD, PhD (16) · David A. Reardon, MD (15) · Giselle Sholler, MD (14) · Henry S. Friedman, MD (14) · David Peereboom, MD (12) · John Boockvar, MD (12) · Stuart A. Grossman, MD (12) · Brian Kushner, MD (11) · Maryam Fouladi, MD (11)
PMID 31401903, PMID 23633099, PMID 34171339, PMID 38335473, PMID 19269895, PMID 32691060, PMID 36346112, PMID 38968568, PMID 39777725, PMID 15758009, PMID 23545055, PMID 24552317, PMID 25098701, PMID 25113840, PMID 29023494, PMID 29982805, PMID 34081125, PMID 34331515, PMID 35468680, PMID 37142373, PMID 37540556, PMID 12749708, PMID 16200343, PMID 16520474, PMID 17369569, PMID 17705175, PMID 19171714, PMID 19556464, PMID 19805691, PMID 20567002, PMID 20694800, PMID 20847174, PMID 20879881, PMID 21865400, PMID 22682017, PMID 23243055, PMID 23377664, PMID 23817721, PMID 23940216, PMID 24101040, PMID 24309981, PMID 24327518, PMID 24344045, PMID 24552318, PMID 24893855, PMID 25209242, PMID 26169613, PMID 27424289, PMID 27465021, PMID 27580889
U10CA098543 (49), U10CA180886 (45), P30CA033572 (24), U01CA062475 (23), U01CA081457 (23), 2023 (21), UM1CA081457 (18), 2009 (16), P01CA081403 (16), 2018 (15), 2014 (13), P30CA008748 (13), UM1CA137443 (13), 2017 (12), U10CA025224 (12)